Loss of smarcad1a accelerates tumorigenesis of malignant peripheral nerve sheath tumors in zebrafish

被引:3
|
作者
Han, Han [1 ]
Jiang, Guangzhen [1 ]
Kumari, Rashmi [1 ]
Silic, Martin R. [1 ]
Owens, Jake L. [2 ]
Hu, Chang-Deng [2 ,3 ]
Mittal, Suresh K. [1 ,3 ,4 ]
Zhang, GuangJun [1 ,3 ,4 ,5 ,6 ]
机构
[1] Purdue Univ, Dept Comparat Pathobiol, 625 Harrison St, W Lafayette, IN 47906 USA
[2] Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47906 USA
[3] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47906 USA
[4] Purdue Univ, Purdue Inst Inflammat Immunol & Infect Dis PI4D, W Lafayette, IN 47906 USA
[5] Purdue Univ, Purdue Inst Integrat Neurosci, W Lafayette, IN 47906 USA
[6] Nanjing Agr Univ, Coll Anim Sci & Technol, Nanjing, Peoples R China
基金
美国国家卫生研究院;
关键词
CRISPR; MPNST; SMARCAD1; smarcad1a; tp53; DNA damage repair; zebrafish; 4q22-23; MESSENGER-RNA DECAY; GENOME DUPLICATION; CHROMATIN; GENES; DNA; IDENTIFICATION; EXPRESSION; FAMILY; DELETION; SURVIVAL;
D O I
10.1002/gcc.22983
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Malignant peripheral nerve sheath tumors (MPNSTs) are a type of sarcoma that generally originates from Schwann cells. The prognosis for this type of malignancy is relatively poor due to complicated genetic alterations and the lack of specific targeted therapy. Chromosome fragment 4q22-23 is frequently deleted in MPNSTs and other human tumors, suggesting tumor suppressor genes may reside in this region. Here, we provide evidence that SMARCAD1, a known chromatin remodeler, is a novel tumor suppressor gene located in 4q22-23. We identified two human homologous smarcad1 genes (smarcad1a and smarcad1b) in zebrafish, and both genes share overlapping expression patterns during embryonic development. We demonstrated that two smarcad1a loss-of-function mutants, sa1299 and p403, can accelerate MPNST tumorigenesis in the tp53 mutant background, suggesting smarcad1a is a bona fide tumor suppressor gene for MPNSTs. Moreover, we found that DNA double-strand break (DSB) repair might be compromised in both mutants compared to wildtype zebrafish, as indicated by pH2AX, a DNA DSB marker. In addition, both SMARCAD1 gene knockdown and overexpression in human cells were able to inhibit tumor growth and displayed similar DSB repair responses, suggesting proper SMARCAD1 gene expression level or gene dosage is critical for cell growth. Given that mutations of SMARCAD1 sensitize cells to poly ADP ribose polymerase inhibitors in yeast and the human U2OS osteosarcoma cell line, the identification of SMARCAD1 as a novel tumor suppressor gene might contribute to the development of new cancer therapies for MPNSTs.
引用
收藏
页码:743 / 761
页数:19
相关论文
共 50 条
  • [31] Clinical Outcomes of Carbon Ion Radiation Therapy for Malignant Peripheral Nerve Sheath Tumors
    Fiore, Maria Rosaria
    Chalaszczyk, Agnieszka
    Barcellini, Amelia
    Vitolo, Viviana
    Fontana, Giulia
    Russo, Stefania
    Rotondi, Marco
    Molinelli, Silvia
    Mirandola, Alfredo
    Bazani, Alessia
    Orlandi, Ester
    ADVANCES IN RADIATION ONCOLOGY, 2024, 9 (11)
  • [32] Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance
    Venturini, Lorenza
    Daidone, Maria Grazia
    Motta, Rosita
    Cimino-Reale, Graziella
    Hoare, Stacey F.
    Gronchi, Alessandro
    Folini, Marco
    Keith, William Nicol
    Zaffaroni, Nadia
    NEURO-ONCOLOGY, 2012, 14 (06) : 736 - 744
  • [33] The CoREST complex is a therapeutic vulnerability in malignant peripheral nerve sheath tumors
    Soukar, Imad
    Fisher, Robert J.
    Bhagavatula, Sanjana
    Collard, Marianne
    Cole, Philip A.
    Alani, Rhoda M.
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [34] Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors
    Cooper, Jonathan M.
    Patel, Amish J.
    Chen, Zhiguo
    Liao, Chung-Ping
    Chen, Kun
    Mo, Juan
    Wang, Yong
    Le, Lu Q.
    CLINICAL CANCER RESEARCH, 2019, 25 (11) : 3404 - 3416
  • [35] Tumor targeted delivery of doxorubicin in malignant peripheral nerve sheath tumors
    Madhankumar, A. B.
    Mrowczynski, Oliver D.
    Slagle-Webb, Becky
    Ravi, Vagisha
    Bourcier, Alexandre J.
    Payne, Russell
    Harbaugh, Kimberly S.
    Rizk, Elias
    Connor, James R.
    PLOS ONE, 2018, 13 (01):
  • [36] Survivin Is a Viable Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors
    Ghadimi, Markus P.
    Young, Eric D.
    Belousov, Roman
    Zhang, Yiqun
    Lopez, Gonzalo
    Lusby, Kristelle
    Kivlin, Christine
    Demicco, Elizabeth G.
    Creighton, Chad J.
    Lazar, Alexander J.
    Pollock, Raphael E.
    Lev, Dina
    CLINICAL CANCER RESEARCH, 2012, 18 (09) : 2545 - 2557
  • [37] Incidence and prognosis of distant metastasis in malignant peripheral nerve sheath tumors
    Xu, Yao
    Xu, Guijun
    Liu, Zheng
    Duan, Jincai
    Lin, Yile
    Zhu, Jiajia
    Baklaushev, Vladimir P.
    Chekhonin, Vladimir P.
    Peltzer, Karl
    Wang, Guowen
    Wang, Xin
    Zhang, Chao
    ACTA NEUROCHIRURGICA, 2021, 163 (02) : 521 - 529
  • [38] Personal and Familial Malignancy History in Patients with Malignant Peripheral Nerve Sheath Tumors with a Focus on Sporadic Tumors
    Pendleton, Courtney
    Everson, Megan C.
    Puffer, Ross C.
    Spinner, Robert J.
    WORLD NEUROSURGERY, 2020, 141 : E778 - E782
  • [39] Genomic profiling and pathological assessment of malignant peripheral nerve sheath tumors
    Qian Cui
    Fen Zhang
    Jian Liu
    Jie Xu
    Hongmei Wu
    Fangping Xu
    Qingling Zhang
    Journal of Cancer Research and Clinical Oncology, 151 (5)
  • [40] Neuropathic Pain Following Surgery for Malignant Peripheral Nerve Sheath Tumors
    Raasveld, Floris V.
    Hanna, Tareq
    Pacheco, Fernando J.
    Gonzalez, Marcos R.
    Johnston, Benjamin
    Lozano-Calderon, Santiago A.
    Valerio, Ian L.
    Eberlin, Kyle R.
    ANNALS OF SURGICAL ONCOLOGY, 2025, : 3741 - 3751